ABSTRACT
Existen importantes diferencias en la prevalencia de la hipertensión según la región geográfica y de desviaciones moderadas en la media cuando se comparan las distintas comunidades de cada país. Los patrones geográficos de la hipertensión se relacionan más con el desarrollo social y económico que determinan algunos perfiles de conducta con respecto a la dieta, frecuencia de obesidad y con diferencias genéticas, en vez de con factores climáticos o naturales (AU)
Subject(s)
Female , Male , Humans , Hypertension/ethnology , Ethnicity , Prevalence , Hypertension/genetics , New Zealand/epidemiology , Europe/epidemiology , China/epidemiology , United States/epidemiology , Phenotype , Ethnicity/genetics , Socioeconomic Factors , Risk FactorsABSTRACT
No disponible
Subject(s)
Humans , Diuretics/pharmacology , Heart Failure/drug therapy , Diuretics/classification , Signs and Symptoms , Spironolactone/pharmacology , Aldosterone/biosynthesis , Bumetanide/pharmacologyABSTRACT
This article presents the program for training in cardiology. The document was elaborated by the National Committee of the Specialty of Cardiology, from the Ministry of Health and Ministry of Education, and describes the theoretical and practical aspects of training in cardiology prevailing at present in Spain.
Subject(s)
Cardiology/education , Education, Medical , Specialization , Cardiology/standards , Curriculum/standards , Medicine/standards , SpainABSTRACT
OBJECTIVES: We sought to evaluate whether pravastatin treatment increases myocardial perfusion, as assessed by thallium-201 single-photon emission computed tomographic (SPECT) dipyridamole testing, in patients with coronary artery disease (CAD) and average cholesterol levels. BACKGROUND: Previous studies in hypercholesterolemic patients have demonstrated that cholesterol reduction restores peripheral and coronary endothelium-dependent vasodilation and increases myocardial perfusion. METHODS: This was a randomized, placebo-controlled study with a cross-over design. Twenty patients with CAD were randomly assigned to receive 20 mg of pravastatin or placebo for 16 weeks and then were crossed over to the opposite medication for a further 16 weeks. Lipid and lipoprotein analysis and dipyridamole thallium-201 SPECT were performed at the end of each period. The SPECT images were visually analyzed in eight myocardial segments using a 4-point scoring system by two independent observers. A summed stress score and a summed rest score were obtained for each patient. Quantitative evaluation was performed by the Cedars-Sinai method. The magnitude of the defect was expressed as a percentage of global myocardial perfusion. RESULTS: Total and low density lipoprotein cholesterol levels during placebo were 214 +/- 29 mg/dl and 148 +/- 25 mg/dl, respectively. These levels with pravastatin were 170 +/- 23 mg/dl and 103 +/- 23 mg/dl, respectively. The summed stress score and summed rest score were lower with pravastatin than with placebo (7.2 +/- 2.3 vs. 5.9 +/- 2.3, p = 0.012 and 3.2 +/- 1.6 vs. 2.4 +/- 2.2, p = 0.043, respectively). Quantitative analysis showed a smaller perfusion defect with pravastatin (29.2%) as compared with placebo (33.8%) (p = 0.021) during dipyridamole stress. No differences were found at rest. CONCLUSIONS: Reducing cholesterol levels with pravastatin in patients with CAD improves myocardial perfusion during dipyridamole stress thallium-201 SPECT.
